Rachel Nugent, PhD, MA is Vice President for Global Non-communicable Diseases at RTI International. She joined RTI in February 2016 to lead a new global initiative to prevent and reduce the health and economic burdens of chronic non-communicable diseases in low- and middle-income countries. Prior to this position, Dr. Nugent was Associate Professor in the Department of Global Health at the University of Washington and Director of the Disease Control Priorities Network. She has advised the World Health Organization, the U.S. Government, and non-profit organizations on the economics and policy environment of NCDs. She is a member of WHO’s Expert Advisory Panel on Management of Non Communicable Diseases (NCDs), the NCD Alliance External Advisory Panel, and The Lancet Commission on NCDIs of the Poorest Billion. Dr. Nugent focuses on using economic analysis for priority-setting in health, and has worked with global and national institutions to increase use of evidence for decision-making. Her current research includes tracking donor funding on NCDs and assessing costs and benefits of NCD policies and interventions. She received her M.Phil. and Ph.D. degrees in economics from the George Washington University
Gillian Sanders-Schmidler, PhD is a Professor of Medicine at Duke University Medical Center. Dr. Sanders-Schmidler received her undergraduate degree in Mathematics from Princeton University in 1993 and her doctorate in Medical Informatics from Stanford University in 1998. She was an Assistant Professor of Medicine at Stanford’s Center for Primary Care and Outcomes Research from 1998 through 2003 when she joined the faculty at Duke University. Her research focuses on the development of evidence-based decision models to evaluate the comparative effectiveness of alternative prevention, treatment, and management strategies for chronic diseases – and the translation of such models into formats/tools that patients, healthcare providers, and policymakers can use in decision-making. Dr. Sanders-Schmidler is Past President of the Society for Medical Decision Making (SMDM). She served as Director of Duke’s Evidence-based Practice Center (EPC III) funded by the Agency for Healthcare Research and Quality (AHRQ) from 2009-2013, and is current Director of the Duke EPC V 2014-2019. She directs Duke’s Evidence Synthesis Group. She recently co-chaired the 2nd Panel for Cost Effectiveness in Health and Medicine.
Moderator and Speaker Bios
Sergio Bautista-Arredondo, MS is Director of the Division of Health Economics and Health Systems Innovations at the National Institute of Public Health of Mexico (INSP) and a visiting scholar at UC Berkeley. He is a health economist with over 15 years of experience in implementation science, with a strong focus on impact evaluation of health and social programs, economic evaluation and efficiency and its determinants of health interventions. He is currently the PI of a Gates Foundation-funded project investigating different aspects of HIV prevention efficiency and its determinants across five African countries. Sergio Bautista is also collaborating on several impact evaluations examining novel interventions grounded in behavioral sciences to motivate either better performance among healthcare providers, or health seeking and preventive behavior of distinct populations.
Eran Bendavid, MD, MS is a physician and an Assistant Professor of Medicine at Stanford University with appointments in Infectious Diseases, General Medicine, Stanford Health Policy, and the Woods Institute for the Environment. His research broadly explores how political, social, economic, and natural environments drive health improvements in low- and middle-income countries. His work on the relationship between foreign aid (especially from the US) and reductions in the burden of HIV, malaria, and child mortality has influenced US foreign policy discussions and has been used in formulating and adopting World Health Organization and UNAIDS treatment and prevention guidelines. His field experience includes evaluation and implementation of disease control programs in Liberia, Kenya, South Africa, Zambia, and India. He has been a member of both the HIV and the TB Modeling Consortia, and has consulted with the US President’s Emergency Plan for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US Agency for International Development, and the UN Inter-agency Group for Child Mortality Estimation.
Colin Boyle, MPP, MBA is the Deputy Director of UCSF Global Health Sciences, dedicated to improving health and reducing inequities worldwide. Colin joined UCSF in 2012, after 15 years with the Boston Consulting Group (BCG), where he was a partner and managing director leading many of the firm’s social impact projects, helping industry and non-profit innovators develop new products to combat disease and bring them to market for health impact. At UCSF, Mr. Boyle has focused on analyzing the case for investments in health, playing a supporting role in the Lancet Commission on Investing in Health and contributing to other investment cases for specific conditions. He also has supported or led efforts at UCSF related to malaria, TB, neglected infectious diseases, maternal health, health systems strengthening, and regulatory sciences, and . Mr. Boyle joined the professional faculty at the Haas School of Business at UC Berkeley in (2012), and teaches courses at the graduate level around the leadership and management of social enterprises and nonprofit organizations. He is currently on the board of trustees of the Oakland Museum of California.
William H. Dow, PhD is Kaiser Permanente Professor of Health Economics at the University of California–Berkeley’s School of Public Health. He directs the UC-Berkeley Center on the Economics and Demography of Aging (CEDA), is a Research Associate at the National Bureau of Economic Research, and previously served as Senior Economist at the White House Council of Economic Advisers. He received his PhD in economics from Yale University. Dow’s research analyzes economic aspects of health insurance, health behaviors, and health and demographic outcomes across the globe. Honors include the Kenneth J. Arrow Award given by the International Health Economics Association.
Neelam Sekhri Feachem, MHA, has over 35 years of experience in health policy, financing, and health systems management. She is Associate Professor in Global Health Sciences, at the University of California, San Francisco (UCSF), and Course Director for Comparative Health Systems and Health Financing in the MS in Global Health. She also teaches in a variety of UCSF and University of California, Berkeley (UCB) programs, including the UCB Global Health Leadership Forum. From 2003– 2007, Lady Feachem served as health financing and policy advisor at the WHO, where she provided technical guidance to a range of countries. More recently, she was Senior Vice President, Global Access and Alliances at a San Francisco-based biotechnology firm. As founder and CEO of The Healthcare Redesign Group since 1994, Ms. Feachem advised governments and international organizations on health reform, financing, and policy. Previously, she spent fourteen years with Kaiser Permanente where she held executive positions in hospital and medical group management. Ms. Feachem has served on numerous Boards including the Commercial Advisory Board of the British National Health Service, the OECD Working Group on Private Insurance, the Alameda County Medical Center, Girls Inc. of Alameda County, INMED Partnerships for Children, and Aravind Eye Foundation. She has published on public private partnerships, access to essential medicines, regulation of health insurance markets, and quality and efficiency of health systems.
Rita Hamad, MD, PhD, is a social epidemiologist and family physician at Stanford University. She will be joining the faculty in Family and Community Medicine at UCSF in April. Her research involves the use of interdisciplinary causal inference methods and big data linkages to examine the social determinants of health. In particular, she investigates how social and economic policies influence health disparities over the life course. In her work, she exploits natural experiments, such as the Great Recession or variation in the earned income tax credit. She was recently awarded a K08 grant from the NIH to evaluate the effects of education policy on cardiovascular disease.
Mark Hlatky, MD is a professor of Health Research and Policy and of medicine (cardiovascular medicine) at Stanford, as well as a CHP/PCOR fellow. His major interests are in outcomes research, evidence-based medicine, and cost-effectiveness analysis. He introduced data collection about economic and quality of life endpoints in several randomized trials, principally trials of therapies for cardiovascular disease. Dr. Hlatky received his MD from the University of Pennsylvania, and, after residency at the University of Arizona, studied as a Robert Wood Johnson Clinical Scholar at the UCSF. He trained in cardiology at Duke University Medical Center, and then joined the Duke faculty. He has been at the Stanford University School of Medicine since 1989, where he is currently professor and chair of Health Research and Policy.
Jeroen P Jansen, PhD is Chief Scientist for Evidence Synthesis and Decision Modeling at Precision Health Economics (PHE), and was a Founding Partner of Redwood Outcomes, now part of PHE. Dr. Jansen has 15 years of experience with meta-analysis, network meta-analysis, cost-effectiveness modeling, and health technology assessment submissions. He is trained as an epidemiologist (Erasmus University, The Netherlands), has an adjunct appointment at Tufts University School of Medicine, and lectures in meta-analysis at Stanford University. He has a strong interest in methods for evidence synthesis, and developed network meta-analysis models for time-to-event data, repeated measures, and integration of patient with study level data, among other. Furthermore, Dr Jansen has been instrumental in developing guidelines on how policymakers and health-care professionals can use evidence from network meta-analysis in clinical decision making, and contributed to the development of reporting guidelines. He has published many papers related to epidemiology, evidence synthesis, and economic evaluations, was an associate editor of Research Synthesis Methods, and is a co-author of a textbook on network meta-analysis for decision-making, to be published soon by Wiley.
James G. Kahn, MD, MPH, is professor in the Philip R. Lee Institute for Health Policy Studies, Global Health Sciences), and the Department of Epidemiology and Biostatistics at UCSF. He is the founder and director of the UCSF Global Health Economics Consortium (GHECon). Dr. Kahn is an expert in cost-effectiveness analysis and associated methods of decision analysis, systematic review, meta-analysis, and costing. Dr. Kahn is the PI for the Consortium for the Assessment of Prevention Economics (CAPE), a multi-institution collaboration working with CDC to examine prevention and treatment strategies. He is also the PI for the UCSF component of a NIDA-funded modeling consortium now in year 18 of 20. He was the PI for Global Health Decisions, which examined efficacy data for interventions for 8 global health conditions. He is co-founder and UCSF PI for the Global Health Cost Consortium, a Gates Foundation-funded project to increase the availability and quality of cost data for treatment and prevention programs for HIV, TB, and other diseases. Dr. Kahn has been funded by NIH, HRSA, CDC, UNAIDS, WHO, the Institute for Cost-Effectiveness Research (ICER), the Bill and Melinda Gates Foundation, the Robert Wood Johnson Foundation, the Kaiser Family Fund, Kaiser Permanente Health Plan, and several private companies. He teaches three economics courses at UCSF.
Dhruv Kazi, MD, MSc, MS, FAHA is a general cardiologist, outcomes researcher, and health economist at UCSF. His work focuses on improving long-term clinical outcomes among patients with cardiovascular disease in resource-scarce settings in the United States and overseas. Projects include the evaluation of health policies, novel diagnostic approaches, medical devices, drug therapy, and genetic testing using simulation modeling and the application of advanced statistical techniques to large observational datasets. He has examined the economics of the healthcare workforce in the US and in India, China, and Sub-Saharan Africa. His research aims to optimize health care expenditures to maximize societal value, including innovative solutions to expand the health care pie (e.g., low-cost mobile technologies or synergies between communicable and non-communicable diseases). Dr Kazi trained in India (Seth G.S. Medical College, Mumbai), Kenya (Moi University, Eldoret), the UK (London School of Economics and Political Science), and the US (Baylor College of Medicine; UC San Diego; Stanford University). He is a World Heart Federation Emerging Leader, an Asia21 Young Leader, and a UCSF Hellman Family Foundation Fellow. He serves as on the American Heart Association’s International Committee, and is an associate editor for Global Heart. When not torturing data, he enjoys portrait photography, rock climbing, and scuba diving.
Elliot Marseille, DrPH, MPP, is principal of the firm, Health Strategies International in Oakland, California that specializes in the economic evaluation of global health programs. Trained in health policy analysis, Dr. Marseille has over 30 years of senior public health management and research experience with a focus on the empirical and modeled assessment of the cost and cost-effectiveness of programs, and policies related to HIV/AIDS. He is currently a consultant to UCSF’s Center for Global Surgical Studies and teaches decision analysis at UCSF. He is a senior analyst for the Consortium for the Assessment of Prevention Economics (CAPE) project, a multi-institution, five-year cooperative agreement designed to extend CDC’s modeling capacity for HIV, HCV, school health, STIs and TB. Current interests also include examining the ethical foundations of cost-effectiveness analysis, identifying sound criteria for judging cost-effectiveness and, as part of the Gates Foundation-funded Global Health Cost Consortium, leveraging existing cost data to more effectively to inform economic appraisal of HIV and TB programs.
Kristine Madsen, MD, MPH is an Associate Professor and Head of the Interdisciplinary Division at UC Berkeley’s School of Public Health. She is a pediatrician and research scientist studying pediatric obesity and health inequalities. With funding from the NIH, the American Heart Association, and the Robert Wood Johnson Foundation, she works to identify policies that will improve the nutrition and physical-activity environments for youth and their families. She has partnered with schools, health departments, and cities to expand the reach of school and after-school programs, and to improve the link between clinics and communities. Her research team recently conducted the first study to examine the impact of Berkeley’s soda tax on sugar-sweetened beverage consumption in low-income neighborhoods in Berkeley.
Douglas K. Owens, MD, MS, is the Henry J. Kaiser, Jr., Professor at Stanford University, where he is a professor of medicine, and, by courtesy, of health research and policy, and of management science and engineering. As director of the Center for Health Policy in the Freeman Spogli Institute for International Studies and director of the Center for Primary Care and Outcomes Research (PCOR) in the Department of Medicine, Dr. Owens leads an interdisciplinary group of Stanford researchers who assess health policy both domestically and internationally. He is a general internist and associate director of the Center for Innovation to Implementation at the Veterans Affairs Palo Alto Health Care System. His research focuses on technology assessment, cost-effectiveness analysis, evidence synthesis, and methods for clinical decision making, with much of his work centered on HIV and cardiovascular disease. Dr. Owens chaired the Clinical Guidelines Committee of the American College of Physicians. He also served on the United States Preventive Services Task Force (USPSTF), which creates national guidelines on prevention services. Recently, he has helped lead the development of guidelines on screening for HIV, hepatitis C, hepatitis B, lung cancer, colorectal cancer, breast cancer, and use of aspirin and statins to prevent cardiovascular disease. He also serves on a committee that is developing guidelines for the conduct of economic analyses for health care in the United States and abroad.
Neil R. Powe, MD, MPH, MBA is the Constance B. Wofsy Distinguished Professor of Medicine, Chief of Medicine at the Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Vice-Chair of Medicine at UCSF. He has experience in patient-oriented research, clinical epidemiology and outcomes and effectiveness research using randomized controlled trials, cohort studies, cost-effectiveness analysis, meta-analysis, retrospective analyses of administrative databases and survey research. He has developed, measured and promulgated the assessment of patient outcomes in chronic kidney disease. He is member of the Methodology Committee of the Patient Centered Outcomes Research Institute.
Justin White, PhD, is Assistant Professor of Health Economics in the UCSF School of Medicine, with joint appointments in the Philip R. Lee Institute for Health Policy Studies and the Department of Epidemiology and Biostatistics. He studies how monetary and social incentives can be used to promote health behavior change, informed by research from the field of behavioral economics. Much of his work focuses on chronic disease prevention, notably smoking cessation, in low- and middle-income countries. Recent and ongoing projects involve evaluations of the health impacts of economic and social policies, including: sin taxes, cash and food assistance programs, and poverty alleviation programs. Prior to joining UCSF, Dr. White completed a postdoctoral fellowship in cardiovascular disease prevention at Stanford University. He holds a PhD in health policy and a concurrent MA in economics from UC Berkeley. He also holds an MSP.H. in health policy from UNC Chapel Hill.
Jinoos Yazdany, MD MPH, is the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases and Associate Professor of Medicine, in Residence at the University of California, San Francisco (UCSF). She is a practicing rheumatologist and has an active health services research program focused on improving health care and outcomes for patients with chronic rheumatic diseases. Dr. Yazdany received her medical degree from the University of California, Los Angeles, her MPH from Harvard University, and completed her residency and rheumatology fellowship at UCSF. She has Co-Chaired the American College of Rheumatology's (ACR) Quality Measures Subcommittee, Chaired the ACR’s Rheumatoid Arthritis Quality Measures Development Work Group, and currently Chairs the Research Committee for the ACR electronic health record-enabled registry, RISE. She also serves on the National Quality Forum's Health Professionals Council. She is the recipient of the 2007 Arthritis Foundation's Arthritis Investigator Award, a National Institute of Arthritis, Musculoskeletal and Skin (NIAMS) Career Development Award, the Hulda Irene Duggan Arthritis Investigator Award, and the 2011 Lupus Foundation of America’s Mary Betty Stevens Young Investigator Prize.